- Home
- COEP vs PYPD Comparison
COEP vs PYPD Comparison
Compare COEP & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | COEP | PYPD |
|---|---|---|
| Founded | 2017 | 2008 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 100.4M | 66.2M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | COEP | PYPD |
|---|---|---|
| Price | $14.45 | $4.00 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $12.00 |
| AVG Volume (30 Days) | ★ 104.9K | 85.7K |
| Earning Date | 11-14-2025 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $500,996.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.31 | $2.30 |
| 52 Week High | $21.41 | $4.10 |
Technical Indicators
Market Signals| Indicator | COEP | PYPD |
|---|---|---|
| Relative Strength Index (RSI) | 43.24 | 62.32 |
| Support Level | $13.61 | $3.89 |
| Resistance Level | $15.40 | $4.10 |
| Average True Range (ATR) | 1.07 | 0.10 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 29.77 | 76.19 |
Price Performance
Historical ComparisonAbout COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.